These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15061044)

  • 21. [The usefulness of capillaroscopy for the evaluation of pulsed magnetic field therapy in patients with primary and secondary Raynaud's phenomenon].
    Kuryliszyn-Moskal A; Kita J; Dakowicz A; Klimiuk PA
    Ann Acad Med Stetin; 2011; 57(3):17-22; discussion 22. PubMed ID: 23383543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
    Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
    Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E; Hsu VM; Impens AJ; Rothman JA; McCloskey DA; Wilson JE; Phillips K; Seibold JR
    J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon.
    Darton K; Black CM
    Br J Rheumatol; 1991 Jun; 30(3):190-5. PubMed ID: 2049579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.
    Muir AH; Robb R; McLaren M; Daly F; Belch JJ
    Vasc Med; 2002; 7(4):265-7. PubMed ID: 12710841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon.
    Anderson ME; Moore TL; Lunt M; Herrick AL
    Rheumatology (Oxford); 2007 Mar; 46(3):533-8. PubMed ID: 17018538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thermography and nailfold capillaroscopy as noninvasive measures of circulation in children with Raynaud's phenomenon.
    Jayanetti S; Smith CP; Moore T; Jayson MI; Herrick AL
    J Rheumatol; 1998 May; 25(5):997-9. PubMed ID: 9598906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud's phenomenon.
    Schmidt J; Monnet P; Normand B; Fabry R
    Vasa; 2005 May; 34(2):93-100. PubMed ID: 15968890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of thermographic criteria to identify Raynaud's phenomenon in a population setting.
    Cherkas LF; Carter L; Spector TD; Howell KJ; Black CM; MacGregor AJ
    J Rheumatol; 2003 Apr; 30(4):720-2. PubMed ID: 12672189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease].
    Yokota S; Kuriyama T; Takahashi Y; Mori M; Shike H; Ibe M; Mitsuda T; Aihara Y
    Ryumachi; 1994 Dec; 34(6):955-60. PubMed ID: 7863385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
    Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
    Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.
    Hirschl M; Hirschl K; Lenz M; Katzenschlager R; Hutter HP; Kundi M
    Arthritis Rheum; 2006 Jun; 54(6):1974-81. PubMed ID: 16732585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
    Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
    Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis.
    Pauling JD; Shipley JA; Harris ND; McHugh NJ
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S103-15. PubMed ID: 22691218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of thoracic outlet syndrome on the epidemiology and clinical presentation of apparently primary Raynaud's phenomenon. A prospective study in 570 patients.
    Pistorius MA; Planchon B
    Int Angiol; 1995 Mar; 14(1):60-4. PubMed ID: 7658106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.
    Thompson AE; Pope JE
    Rheumatology (Oxford); 2005 Feb; 44(2):145-50. PubMed ID: 15546967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
    Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
    Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.